| scholarly article | Q13442814 |
| P356 | DOI | 10.1586/14737167.5.6.751 |
| P698 | PubMed publication ID | 19807617 |
| P2093 | author name string | Marc S Sabatine | |
| Sean M Donahoe | |||
| P2860 | cites work | A Comparison of Recombinant Hirudin with Heparin for the Treatment of Acute Coronary Syndromes | Q56945341 |
| ACC/AHA 2004 Guideline Update for Coronary Artery Bypass Graft Surgery: Summary Article | Q56986928 | ||
| ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction—Executive Summary | Q56986933 | ||
| ACC/AHA Guidelines for Percutaneous Coronary Intervention (Revision of the 1993 PTCA Guidelines)—Executive Summary | Q58975787 | ||
| The TIMI Risk Score for Unstable Angina/Non–ST Elevation MI | Q22252998 | ||
| Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients | Q24555072 | ||
| Central role of the P2Y12 receptor in platelet activation | Q24618777 | ||
| Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study | Q28165412 | ||
| Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction | Q28168881 | ||
| Clopidogrel resistance: a new chapter in a fast-moving story | Q28169150 | ||
| Cost-effectiveness of clopidogrel | Q28174908 | ||
| Trends in treatment and outcomes for acute myocardial infarction: 1975-1995 | Q28175989 | ||
| Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: a meta-analysis of phase III multicenter randomized trials | Q28176219 | ||
| Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial | Q28181168 | ||
| Balancing the benefit and risk of oral antiplatelet agents in coronary artery bypass surgery | Q28184971 | ||
| Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban | Q28185502 | ||
| Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial | Q28185728 | ||
| Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation | Q28188284 | ||
| Meta-analysis of randomized and registry comparisons of ticlopidine with clopidogrel after stenting | Q28191931 | ||
| The effect of clopidogrel in combination with aspirin when given before coronary artery bypass grafting | Q28193370 | ||
| Benefit of clopidogrel in patients with acute coronary syndromes without ST-segment elevation in various risk groups | Q28193817 | ||
| Resistance to aspirin in vitro is associated with increased platelet sensitivity to adenosine diphosphate | Q28194108 | ||
| Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial | Q28194232 | ||
| Early and late effects of clopidogrel in patients with acute coronary syndromes | Q28195029 | ||
| Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity | Q28196405 | ||
| Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials | Q28202129 | ||
| Long-term cost-effectiveness of clopidogrel given for up to one year in patients with acute coronary syndromes without ST-segment elevation | Q28210312 | ||
| Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial | Q28210890 | ||
| Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial | Q28211092 | ||
| Antithrombotic therapy for coronary artery disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy | Q28213459 | ||
| Effects of reviparin, a low-molecular-weight heparin, on mortality, reinfarction, and strokes in patients with acute myocardial infarction presenting with ST-segment elevation | Q28213755 | ||
| Variability in response to aspirin: do we understand the clinical relevance? | Q28217618 | ||
| Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation | Q28218789 | ||
| An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. The GUSTO investigators | Q28254763 | ||
| Intensive versus moderate lipid lowering with statins after acute coronary syndromes | Q29619716 | ||
| A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee | Q29620666 | ||
| Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting : the clopidogrel aspirin stent international cooperative study | Q33333456 | ||
| A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. | Q33504515 | ||
| Effect of early intravenous heparin on coronary patency, infarct size, and bleeding complications after alteplase thrombolysis: results of a randomised double blind European Cooperative Study Group trial | Q33611581 | ||
| The pathophysiology of acute coronary syndromes | Q33839207 | ||
| Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction | Q34168972 | ||
| A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents | Q34374902 | ||
| Early thrombolytic treatment in acute myocardial infarction: reappraisal of the golden hour | Q34398044 | ||
| Sudden death due to cardiac arrhythmias | Q34496008 | ||
| Expert consensus document on the use of antiplatelet agents. The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European society of cardiology | Q35628214 | ||
| Pharmacoinvasive therapy: the future of treatment for ST-elevation myocardial infarction | Q35789802 | ||
| Resistance to clopidogrel: a review of the evidence | Q36101144 | ||
| Preclinical and clinical studies with selective reversible direct P2Y12 antagonists | Q36106325 | ||
| The pathogenesis of coronary artery disease and the acute coronary syndromes (1). | Q36728740 | ||
| Vulnerable plaque: pathobiology and clinical implications | Q38548243 | ||
| Relation of the site of acute myocardial infarction to the most severe coronary arterial stenosis at prior angiography | Q39237218 | ||
| Twenty-two year (1975 to 1997) trends in the incidence, in-hospital and long-term case fatality rates from initial Q-wave and non-Q-wave myocardial infarction: a multi-hospital, community-wide perspective | Q39566715 | ||
| Variability in platelet responsiveness to clopidogrel among 544 individuals. | Q40454244 | ||
| Coronary Plaque Disruption | Q40459835 | ||
| The benefits of aspirin in acute myocardial infarction. Still a well-kept secret in the United States | Q40793928 | ||
| Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction | Q40985280 | ||
| Can coronary angiography predict the site of a subsequent myocardial infarction in patients with mild-to-moderate coronary artery disease? | Q41263009 | ||
| The in vivo pharmacological profile of CS-747, a novel antiplatelet agent with platelet ADP receptor antagonist properties | Q41906079 | ||
| A simple risk index for rapid initial triage of patients with ST-elevation myocardial infarction: an InTIME II substudy | Q42043575 | ||
| Effects of reteplase and alteplase on platelet aggregation and major receptor expression during the first 24 hours of acute myocardial infarction treatment. GUSTO-III Investigators. Global Use of Strategies to Open Occluded Coronary Arteries | Q42679152 | ||
| Analysis of the relative costs and effectiveness of primary angioplasty versus tissue-type plasminogen activator: the Primary Angioplasty in Myocardial Infarction (PAMI) trial. The PAMI Trial Investigators | Q43645713 | ||
| Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction | Q43724527 | ||
| A comparison of reteplase with alteplase for acute myocardial infarction | Q44205469 | ||
| Lysis of plasminogen activator-resistant platelet-rich coronary artery thrombus with combined bolus injection of recombinant tissue-type plasminogen activator and antiplatelet GPIIb/IIIa antibody | Q44372589 | ||
| Effect of heparin on coronary arterial patency after thrombolysis with tissue plasminogen activator in acute myocardial infarction | Q45083112 | ||
| Health and economic benefits of increased beta-blocker use following myocardial infarction | Q46184653 | ||
| Enoxaparin versus unfractionated heparin as antithrombin therapy in patients receiving fibrinolysis for ST-elevation myocardial infarction. Design and rationale for the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatmen | Q46450488 | ||
| The wavefront phenomenon of ischemic cell death. 1. Myocardial infarct size vs duration of coronary occlusion in dogs | Q47325541 | ||
| Clinical and angiographic correlates and outcomes of suboptimal coronary flow inpatients with acute myocardial infarction undergoing primary percutaneous coronary intervention. | Q51792124 | ||
| Differential sensitivity of erythrocyte-rich and platelet-rich arterial thrombi to lysis with recombinant tissue-type plasminogen activator. A possible explanation for resistance to coronary thrombolysis. | Q54357272 | ||
| ACC/AHA Guideline Update for the Management of Patients With Unstable Angina and Non-ST-Segment Elevation Myocardial Infarction--2002: Summary Article: A Report of the American College of Cardiology/American Heart Association Task Force on Practice G | Q55889587 | ||
| Abciximab as Adjunctive Therapy to Reperfusion in Acute ST-Segment Elevation Myocardial Infarction | Q56944163 | ||
| Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial | Q56944998 | ||
| P433 | issue | 6 | |
| P921 | main subject | myocardial infarction | Q12152 |
| aspirin | Q18216 | ||
| clopidogrel | Q410237 | ||
| P304 | page(s) | 751-761 | |
| P577 | publication date | 2005-12-01 | |
| P1433 | published in | Expert Review of Pharmacoeconomics & Outcomes Research | Q15734522 |
| P1476 | title | Adding clopidogrel to aspirin improves outcome in ST-elevation myocardial infarction patients receiving fibrinolytic therapy | |
| P478 | volume | 5 |
| Q38065124 | Comparing newer oral anti-platelets prasugrel and ticagrelor in reduction of ischemic events-evidence from a network meta-analysis. |
| Q36237726 | Efficacy and Safety of Novel Oral P2Y12 Receptor Inhibitors in Patients With ST-Segment Elevation Myocardial Infarction Undergoing PCI: A Systematic Review and Meta-Analysis. |
Search more.